Compound News and Research

RSS

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Study offers hints to why Parkinson's so selectively harms dopamine-producing cells

New data offer hints to why Parkinson's disease so selectively harms brain cells that produce the chemical dopamine, say researchers at Washington University School of Medicine in St. Louis.

13 May 2011

Coffee provides protections from a type of breast cancer: Study

For the study they compared coffee consumption in postmenopausal women with breast cancer and women of the same age without cancer, they found those who drank five or more cups of java a day showed a 0.43 times lower risk of estrogen-receptor negative cancers. Around one in four women diagnosed with breast cancer will have estrogen-receptor negative breast cancer, which is often resilient to drug treatment and requires intensive chemotherapy.

12 May 2011

Nearly one third of the miners on a synthetic form of cannabis

New research has revealed that a synthetic form of cannabis is being consumed and has shown up in one in ten West Australian mine workers’ urine samples. The state's ChemCentre provides forensic testing for police and the State Coroner. They have been given the contract on an increasing basis by private companies in mining regions to test their workers for the substance, known as Kronic.

12 May 2011

Prestige Brands fourth fiscal quarter revenue increases 37.8% to $96.4 million

Prestige Brands Holdings, Inc. today announced results for the fourth fiscal quarter and full year ended March 31, 2011.

12 May 2011

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.

12 May 2011

Sugar boosts effectiveness of first-line antibiotics against chronic bacterial infections

James Collins, a pioneering researcher in the new field of systems biology and a MacArthur Genius, says: "You know the old saying: 'a spoonful of sugar makes the medicine go down?' This is more like 'a spoonful of sugar makes the medicine work.'

12 May 2011

Baylor has now patented new polarimeter that could prove useful in pharmaceuticals

Two Baylor University chemistry professors have invented a new polarimeter, a basic scientific instrument used to measure and interpret the polarization of transverse waves, such as light waves, that could prove useful in determining the purity of pharmaceuticals. Baylor has now patented the device.

11 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

Impax Pharmaceuticals initiates IPX159 Phase I study in Restless Legs Syndrome

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., announced the successful filing of an Investigational New Drug Application for IPX159 in Restless Legs Syndrome and initiated a Phase I study.

11 May 2011

New study finds nitric oxide gas appears to affect source of sickle cell pain crises

Nitric oxide gas appears to directly impact the source of the classic, disabling pain crises of sickle cell disease, Georgia Health Sciences University researchers report.

10 May 2011

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and sunitinib as prior treatments.

10 May 2011

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.

10 May 2011

caprotec bioanalytics closes Series B financing for EUR 5 million

caprotec bioanalytics GmbH, a privately held biopharmaceutical company offering the proprietary Capture Compound Mass Spectrometry platform technology for the analysis of small molecule – protein interactions, today announced a second closing of EUR 1 million to its Series B financing, increasing total equity for the round to EUR 5 million.

9 May 2011

Ideal psychotropic drug may cause physical dependence

A report in the current issue of Psychotherapy and Psychosomatics by a group of European investigators headed by Fabrizio Schifano has explored the potential for dependence of pregabalin using patients' online reports.

9 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

$University of Oregon physicist to design fractal vision devices$

Compound News and Research

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Study offers hints to why Parkinson's so selectively harms dopamine-producing cells

Coffee provides protections from a type of breast cancer: Study

Nearly one third of the miners on a synthetic form of cannabis

Prestige Brands fourth fiscal quarter revenue increases 37.8% to $96.4 million

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Sugar boosts effectiveness of first-line antibiotics against chronic bacterial infections

Baylor has now patented new polarimeter that could prove useful in pharmaceuticals

Naurex announces completion of $18 million Series A financing

Impax Pharmaceuticals initiates IPX159 Phase I study in Restless Legs Syndrome

New study finds nitric oxide gas appears to affect source of sickle cell pain crises

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

caprotec bioanalytics closes Series B financing for EUR 5 million

Ideal psychotropic drug may cause physical dependence

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

University of Oregon physicist to design fractal vision devices

Odyssey Thera receives US patent for application of contextual high-content assays to diverse biological events

TGen licenses ONCO-101 cancer drug to Syracuse

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News